Sign in
CompletedPhase 2

Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders

Key facts

Who runs it
Brown University
Where
Burlington and Providence, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
326 people enrolled
Started
18 Oct 2020
Ended
27 Nov 2023
Type of study
Interventional, 4 groups
Treatments tested
  • Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
  • E-Cigarettes
Record updated
1 April 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Between 21 years and 70 years old
  • Must have current diagnosis of an Affective Disorder

Who cannot take part

  • Being without an Affective Disorder
  • Younger than 21 years old
  • Older than 70 years old

Where in United States

  • University of VermontBurlington, United States
  • Brown UniversityProvidence, United States

About the trial

What the trial wants to find out

While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions. Affective Disorders (ADs) are the most common mental health conditions in the US, and over 40% of people with ADs are current smokers. A national policy of reducing the nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and related adverse health outcomes. Controlled trials in psychiatrically-stable smokers have shown that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse consequences.

Read full original descriptionShow less

The goal of the proposed trial is to experimentally model whether increasing the availability and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) moderates the effect of altering the nicotine in cigarettes in smokers with ADs. Additionally, investigators will test whether allowing participants to personalize the flavor of the e-liquid alters any moderating effects their availability may have on tobacco cigarette smoking.

Daily smokers with current ADs will be recruited at Brown University and the University of Vermont.

Investigators will study two research cigarettes referred to here as Research Cigarette 1 (RC1) and Research Cigarette 2 (RC2). One of these cigarettes will be a normal nicotine content cigarette and the other will be a reduced nicotine content cigarette. Investigators will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially available devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be available only in tobacco flavor while in the other condition that e-liquid will be available in multiple flavors from which participants can choose based on personal taste preference. Participants will be assigned to one of the following four study conditions: (1) RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.

Participants will be asked to use only their assigned study products for 16 weeks. Outcome measures include total CPD, cigarette demand assessed by behavioral economics-based purchase tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional nitric oxide concentration in exhaled breath [FeNO]).

The 4 groups in the trial

  • RC 1 onlyTreatment being tested

    Research Cigarettes #1

    Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

  • RC 2 onlyTreatment being tested

    Research Cigarettes #2

    Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

  • RC 2 + EC 1Treatment being tested

    Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)

    Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g) and E-Cigarettes

  • RC 2 + EC 2Treatment being tested

    Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)

    Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g) and E-Cigarettes

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
1 April 2025